Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming

June 11, 2019 2:00 PM PDT
Goldman Sachs 40th Annual Global Healthcare Conference

Prior

May 21, 2019 10:30 AM EDT
RBC Capital Markets Healthcare Conference

May 20, 2019 3:00 PM EDT
UBS Global Healthcare Conference

May 14, 2019 8:40 AM PDT
Bank of America Merrill Lynch Health Care Conference

SEC Filings

Filing date Description Filing Group View

Statement of changes in beneficial ownership of securities

3,4,5

Report of unscheduled material events or corporate event

Current Reports

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings

Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Kwiecinski
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: lkwiecinski@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536